Literature DB >> 16297193

Increased sensitivity to interferon-alpha in psoriatic T cells.

Karsten Wessel Eriksen1, Paola Lovato, Lone Skov, Thorbjørn Krejsgaard, Keld Kaltoft, Carsten Geisler, Niels Ødum.   

Abstract

Psoriasis is a chronic inflammatory skin disease characterized by abnormal epidermal proliferation. Several studies have shown that skin-infiltrating activated T cells and cytokines play a pivotal role during the initiation and maintenance of the disease. Interferon (IFN)-alpha plays an important role in host defense against infections, but recent data have also implicated IFN-alpha in psoriasis. Thus, IFN-alpha induces or aggravates psoriasis in some patients, and mice lacking a transcriptional attenuator of IFN-alpha/beta signaling spontaneously develop a psoriasis-like inflammatory skin disease characterized by CD8(+)-infiltrating T cells. In this study, we therefore investigate IFN-alpha signaling in T cells isolated from involved skin of psoriatic patients. We show that psoriatic T cells have increased and prolonged responses to IFN-alpha, on the level of signal transducers and activators of transcription (STAT) activation, compared with infiltrating T cells from skin of non-psoriatic donors. Functionally, the increased IFN-alpha signaling leads to an increased binding of STAT4 to the IFN-gamma promotor, IFN-gamma production, and inhibition of T cell growth. In contrast, to STAT responses to other cytokines were not changed in psoriasis. In conclusion, we provide evidence that psoriatic T cells have an increased sensitivity to IFN-alpha. Thus, our data suggest that increased IFN-alpha signaling is involved in the pathogenesis of psoriasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297193     DOI: 10.1111/j.0022-202X.2005.23864.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  25 in total

Review 1.  Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.

Authors:  M Afshar; A D Martinez; R L Gallo; T R Hata
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-06-01       Impact factor: 6.166

Review 2.  Biological therapy for dermatological manifestations of inflammatory bowel disease.

Authors:  Maddalena Zippi; Roberta Pica; Daniela De Nitto; Paolo Paoluzi
Journal:  World J Clin Cases       Date:  2013-05-16       Impact factor: 1.337

Review 3.  Psoriatic arthritis: latest treatments and their place in therapy.

Authors:  Eun Jin Kang; Arthur Kavanaugh
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

4.  Programmed cell death-10 enhances proliferation and protects malignant T cells from apoptosis.

Authors:  Britt Lauenborg; Katharina Kopp; Thorbjørn Krejsgaard; Karsten W Eriksen; Carsten Geisler; Sally Dabelsteen; Robert Gniadecki; Qian Zhang; Mariusz A Wasik; Anders Woetmann; Niels Odum
Journal:  APMIS       Date:  2010-08-19       Impact factor: 3.205

Review 5.  Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.

Authors:  Ennio Lubrano; Fabio Massimo Perrotta
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

6.  Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma.

Authors:  Thorbjørn Krejsgaard; Claudia S Vetter-Kauczok; Anders Woetmann; Hermann Kneitz; Karsten W Eriksen; Paola Lovato; Qian Zhang; Mariusz A Wasik; Carsten Geisler; Elisabeth Ralfkiaer; Juergen C Becker; Niels Ødum
Journal:  Blood       Date:  2009-04-07       Impact factor: 22.113

7.  STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.

Authors:  Katharina L Kopp; Ulrik Ralfkiaer; Lise Mette R Gjerdrum; Rikke Helvad; Ida H Pedersen; Thomas Litman; Lars Jønson; Peter H Hagedorn; Thorbjørn Krejsgaard; Robert Gniadecki; Charlotte M Bonefeld; Lone Skov; Carsten Geisler; Mariusz A Wasik; Elisabeth Ralfkiaer; Niels Ødum; Anders Woetmann
Journal:  Cell Cycle       Date:  2013-05-15       Impact factor: 4.534

Review 8.  The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.

Authors:  Consuelo M López de Padilla; Timothy B Niewold
Journal:  Gene       Date:  2015-09-26       Impact factor: 3.688

9.  Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling.

Authors:  Ally-Khan Somani; Alan R Swick; Kevin D Cooper; Thomas S McCormick
Journal:  Arch Dermatol       Date:  2008-10

10.  IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF).

Authors:  Andreas Willerslev-Olsen; Ivan V Litvinov; Simon M Fredholm; David L Petersen; Nina A Sibbesen; Robert Gniadecki; Qian Zhang; Charlotte M Bonefeld; Mariusz A Wasik; Carsten Geisler; Youwen Zhou; Anders Woetmann; Denis Sasseville; Thorbjørn Krejsgaard; Niels Odum
Journal:  Cell Cycle       Date:  2014-03-03       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.